Figure 7
Figure 7. CMV-seropositive donor PBMCs exposed to CMV antigen results in endothelial damage in cocultures that is mediated predominantly by the fractalkine-CX3CR1 interaction. Each micrograph panel shows the resulting effects of specific neutralizing antibody blocks and controls on CMV-induced endothelial damage in PBMC-AEC cocultures at day 6. Negative control was transmigrated PBMC populations using negative control media lacking chemokines; positive control was transmigrated PBMCs using untreated coculture supernatants; isotype control was PBMCs treated with isotype control antibodies for CX3CR1-specific and RANTES-specific neutralizing antibodies, followed by transmigration into coculture supernatants; anti-CX3CR1 block was PBMCs treated with neutralizing antibody specific for CX3CR1, followed by transmigration into coculture supernatants; anti-RANTES block was PBMCs treated with neutralizing antibody specific for RANTES, followed by transmigration into coculture supernatants; dual block was PBMCs treated with both neutralizing antibody specific for CX3CR1 and neutralizing antibody specific for RANTES, followed by transmigration into coculture supernatants. Extensive endothelial damage and loss are seen in positive control, isotype control, and anti-RANTES block. In contrast, protection against endothelial damage is observed in the presence of the anti–CX3CR1-blocked samples.

CMV-seropositive donor PBMCs exposed to CMV antigen results in endothelial damage in cocultures that is mediated predominantly by the fractalkine-CX3CR1 interaction. Each micrograph panel shows the resulting effects of specific neutralizing antibody blocks and controls on CMV-induced endothelial damage in PBMC-AEC cocultures at day 6. Negative control was transmigrated PBMC populations using negative control media lacking chemokines; positive control was transmigrated PBMCs using untreated coculture supernatants; isotype control was PBMCs treated with isotype control antibodies for CX3CR1-specific and RANTES-specific neutralizing antibodies, followed by transmigration into coculture supernatants; anti-CX3CR1 block was PBMCs treated with neutralizing antibody specific for CX3CR1, followed by transmigration into coculture supernatants; anti-RANTES block was PBMCs treated with neutralizing antibody specific for RANTES, followed by transmigration into coculture supernatants; dual block was PBMCs treated with both neutralizing antibody specific for CX3CR1 and neutralizing antibody specific for RANTES, followed by transmigration into coculture supernatants. Extensive endothelial damage and loss are seen in positive control, isotype control, and anti-RANTES block. In contrast, protection against endothelial damage is observed in the presence of the anti–CX3CR1-blocked samples.

Close Modal

or Create an Account

Close Modal
Close Modal